GlassScriptPhysician profile
Mary Riley Parker
NPI 1861506032
$27,862.81
in general payments reported to CMS, 2019-2025
11 companies · $6,639 in 2025
The $6,639 reported for 2025 was more than what 99% of Phlebology providers received nationally (typical 2025 total: $141).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $153 · 2021: $531 · 2022: $443 · 2023: $9,916 · 2024: $9,846 · 2025: $6,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $25K · Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $25,493.36 |
| Food and Beverage | $907.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $26,100.72 | 2019-2025 | Venacure 1470 Pro, Venacure 1470 Pro |
| Boston Scientific Corporation | $679.46 | 2023-2025 | Varithena Administration Pack, General - Vascular Intervention |
| Biocompatibles, INC. | $244.32 | 2019 | |
| Smith+Nephew, INC. | $243.79 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $175.79 | 2022 | |
| Abbott Laboratories | $148.14 | 2021 | |
| Tactile Systems Technology INC | $106.14 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Medtronic, INC. | $62.51 | 2022-2023 | Closurefast |
| Merz North America, INC. | $45.49 | 2023 | |
| Organogenesis INC. | $34.99 | 2025 | Simplimax |
| Cipher Pharmaceuticals US LLC | $21.46 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.